19Jun 2022
Sentinel lymph node biopsy in high‐risk cutaneous squamous cell carcinoma of the head and neck: Systematic review and meta‐analysis

Sentinel lymph node biopsy in high‐risk cutaneous squamous cell carcinoma of the head and neck: Systematic review and meta‐analysis

The aim of present study was to better define the role of sentinel lymph node biopsy (SLNB) in high‐risk cutaneous squamous cell carcinoma of the head and neck (cSCCHN). A systematic review and meta‐analysis was performed according to the PRISMA statement. Seven‐hundred and five patients were included from 20 studies. The pooled SLN identification rate was 98.8% (95%CI: 97.0–99.8). The median number of SLN excised was 3.6 (n = 371, 95%CI: 2.0–4.4). The pooled SLNB positive rate and cumulative regional recurrence rate (RRR) in negative SLNB were 5.6% (95%CI: 2.6–9.6) and 2.9% (95%CI: 0.5–7.2), respectively. Further studies are mandatory to define predictors of lymph node metastases able to better select patients that may benefit from a SLNB.

  • #ent

Like

Save

Share